ISRCTN20164309 https://doi.org/10.1186/ISRCTN20164309

Second serosurveillance study in The Netherlands for the evaluation of the Dutch National Immunisation Programme: the PIENTER 2 study

Submission date
27/06/2007

Registration date
27/06/2007

Last Edited
18/03/2013

Recruitment status
No longer recruiting

Overall study status
Completed

Condition category
Infections and Infestations

[_] Prospectively registered
[_] Protocol
[_] Statistical analysis plan
[X] Results
[_] Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr F.R.M. van der Klis

Contact details
National Institute of Public Health and Environmental Protection (RIVM)
afdeling LIS
P.O. Box 1
Bilthoven
Netherlands
3720 BA
+31 (0)30 274 2272
fiona.van.der.klis@rivm.nl

Additional identifiers

Protocol serial number
N/A

Study information

Scientific Title

Acronym
PIENTER 2

Study objectives
The age-specific seroprevalence of a cross-section of the Dutch population for the vaccinations used in the Dutch National Immunisation Programme.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Approval received from the local ethics committee (Stichting Therapeutische Evaluatie Geneesmiddelen [STEG]) on the 11th October 2005 (ref: R05-044).

Study design
Observational, cross-section survey

Primary study design
Observational

Study type(s)
Screening

Health condition(s) or problem(s) studied
Vaccination and the National Immunisation Program, infectious diseases

Interventions
A blood sample and a questionnaire regarding health perception, diseases (including sexually transmitted), vaccination data.

Intervention Type
Other

Phase
Not Specified

Primary outcome(s)
The age-specific seroprevalence (immunity) for diseases included in the National Immunisation Program of the Dutch general population.

As each participant is sampled only once, there will be only one timepoint measurement per person. The timepoint for the complete study population varies from February 2006 to June 2007. Because the participants represent a cross section of the Dutch population aged 0 to 80, we will be able to estimate the seroprevalence in the Dutch population in 2006-2007.

Key secondary outcome(s))

1. The age-specific seroprevalence against other infectious diseases, in particular those that might be vaccine preventable in the near future and against those diseases with a frequent subclinical course
2. The age-specific seroprevalence amongst the allochtonous populations (additional sample)
3. The age-specific seroprevalence amongst non-vaccinated orthodox reformed individuals (additional sample)

As each participant is sampled only once, there will be only one timepoint measurement per person. The timepoint for the complete study population varies from February 2006 to June 2007. Because the participants represent a cross section of the Dutch population aged 0 to 80, we will be able to estimate the seroprevalence in the Dutch population in 2006-2007.

Completion date
19/06/2007

Eligibility

Key inclusion criteria
1. Subject is part of the study sample
2. Aged 0 - 79 years old
3. Has received a personal invitation for the study
4. Subject has given written informed consent before start of the study

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Sex
Not Specified

Key exclusion criteria
Subject is an employee of the National Institute of Public Health and Environmental Protection (RIVM).

Date of first enrolment
06/02/2006

Date of final enrolment
19/06/2007

Locations

Countries of recruitment
Netherlands

Study participating centre
National Institute of Public Health and Environmental Protection (RIVM)
Bilthoven
Netherlands
3720 BA

Sponsor information

Organisation
National Institute of Public Health and Environmental Protection (RIVM) (The Netherlands)

ROR
https://ror.org/01cesdt21

Funder(s)

Funder type
Government

Funder Name
The Netherlands Ministry of Health, Welfare and Sport (The Netherlands)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	19/10/2012		Yes	No
Results article	results	01/04/2014		Yes	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes